DE69309915D1 - Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen - Google Patents

Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen

Info

Publication number
DE69309915D1
DE69309915D1 DE69309915T DE69309915T DE69309915D1 DE 69309915 D1 DE69309915 D1 DE 69309915D1 DE 69309915 T DE69309915 T DE 69309915T DE 69309915 T DE69309915 T DE 69309915T DE 69309915 D1 DE69309915 D1 DE 69309915D1
Authority
DE
Germany
Prior art keywords
treatment
protracted
mycobacterium vaccae
autoimmune diseases
immunologically mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69309915T
Other languages
English (en)
Other versions
DE69309915T2 (de
Inventor
John Lawson Stanford
Graham Arthur William Rook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Publication of DE69309915D1 publication Critical patent/DE69309915D1/de
Application granted granted Critical
Publication of DE69309915T2 publication Critical patent/DE69309915T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • External Artificial Organs (AREA)
  • Soil Working Implements (AREA)
DE69309915T 1992-02-21 1993-02-19 Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen Expired - Fee Related DE69309915T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929203814A GB9203814D0 (en) 1992-02-21 1992-02-21 Treatment of long term auto-immune conditions
PCT/GB1993/000351 WO1993016727A1 (en) 1992-02-21 1993-02-19 Mycobacterium vaccae for treatment of long term autoimmune conditions

Publications (2)

Publication Number Publication Date
DE69309915D1 true DE69309915D1 (de) 1997-05-22
DE69309915T2 DE69309915T2 (de) 1997-07-24

Family

ID=10710862

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69328503T Expired - Fee Related DE69328503T2 (de) 1992-02-21 1993-02-19 Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen
DE69309915T Expired - Fee Related DE69309915T2 (de) 1992-02-21 1993-02-19 Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69328503T Expired - Fee Related DE69328503T2 (de) 1992-02-21 1993-02-19 Mycobacterium vaccae zur Behandlung von lang andauernden Autoimmunerkrankungen

Country Status (24)

Country Link
US (1) US5885588A (de)
EP (2) EP0763361B1 (de)
JP (1) JPH07506093A (de)
KR (1) KR100275862B1 (de)
AT (2) ATE151641T1 (de)
AU (2) AU675421B2 (de)
BG (1) BG99054A (de)
BR (1) BR9305946A (de)
CA (1) CA2130117A1 (de)
CZ (1) CZ282651B6 (de)
DE (2) DE69328503T2 (de)
DK (2) DK0763361T3 (de)
ES (2) ES2145968T3 (de)
FI (1) FI943849A0 (de)
GB (1) GB9203814D0 (de)
GR (2) GR3024113T3 (de)
HU (1) HU218347B (de)
NO (1) NO311169B1 (de)
NZ (1) NZ249518A (de)
RO (1) RO117833B1 (de)
RU (1) RU2124367C1 (de)
SK (1) SK99994A3 (de)
UA (1) UA35583C2 (de)
WO (1) WO1993016727A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
IL110011A (en) * 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AU741016B2 (en) * 1996-08-29 2001-11-22 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
DK0951289T3 (da) * 1996-12-18 2006-03-13 Stanford Rook Ltd Anvendelse af Mycobacterium vaccae til behandling af kronisk træthedssyndrom
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
JP2002514385A (ja) * 1997-12-23 2002-05-21 ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド ミコバクテリウム・バッケー由来の組成物およびその使用法
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
WO2001010221A1 (en) * 1999-08-06 2001-02-15 Corixa Corporation Vaccines for the treatment of autoimmune disease
GB0010496D0 (en) * 2000-04-28 2000-06-14 Stanford Rook Ltd Treatment of conditions of the central nervous system
GB0106986D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
JP4875494B2 (ja) * 2003-11-14 2012-02-15 ユーシーエル バイオメディカ ピーエルシー 免疫調節物質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene

Also Published As

Publication number Publication date
RU94045825A (ru) 1997-02-20
NO943082L (no) 1994-10-17
WO1993016727A1 (en) 1993-09-02
EP0763361B1 (de) 2000-04-26
EP0763361A3 (de) 1997-03-26
DK0630259T3 (da) 1997-09-15
DE69328503T2 (de) 2000-08-24
ATE151641T1 (de) 1997-05-15
HU218347B (hu) 2000-08-28
EP0630259A1 (de) 1994-12-28
US5885588A (en) 1999-03-23
FI943849A0 (fi) 1994-08-22
NZ249518A (en) 1997-07-27
UA35583C2 (uk) 2001-04-16
SK99994A3 (en) 1995-05-10
HUT69941A (en) 1995-09-28
GR3024113T3 (en) 1997-10-31
DE69328503D1 (de) 2000-05-31
AU7188796A (en) 1997-02-06
CZ202394A3 (en) 1995-02-15
AU675421B2 (en) 1997-02-06
GR3033772T3 (en) 2000-10-31
GB9203814D0 (en) 1992-04-08
RU2124367C1 (ru) 1999-01-10
ATE192046T1 (de) 2000-05-15
NO943082D0 (no) 1994-08-22
JPH07506093A (ja) 1995-07-06
RO117833B1 (ro) 2002-08-30
AU3637793A (en) 1993-09-13
EP0763361A2 (de) 1997-03-19
ES2104131T3 (es) 1997-10-01
DE69309915T2 (de) 1997-07-24
CZ282651B6 (cs) 1997-08-13
HU9402422D0 (en) 1994-10-28
DK0763361T3 (da) 2000-08-07
EP0630259B1 (de) 1997-04-16
ES2145968T3 (es) 2000-07-16
KR100275862B1 (ko) 2000-12-15
NO311169B1 (no) 2001-10-22
AU706122B2 (en) 1999-06-10
CA2130117A1 (en) 1993-09-02
BG99054A (en) 1995-08-28
KR950700755A (ko) 1995-02-20
BR9305946A (pt) 1997-10-21

Similar Documents

Publication Publication Date Title
DE69309915D1 (de) Mycobacterium Vaccae zur Behandlung von langwierigen Autoimmunerkrankungen
ATE132755T1 (de) Mycobacterium vaccae in der behandlung von uveitis
DK53497A (da) Osteoinduktive præparater
DE69026506D1 (de) Biologisches präparat und seine verwendung
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
DE69207885D1 (de) Gammalinolensäure zur Herstellung eines Medikaments zur Verhinderung von Wiederverschluss von Arterien
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DE3884241D1 (de) Analoge des Porcin-Wachstumshormones.
DE68913779D1 (de) D-Amidase und Verfahren zur Herstellung von D-alpha-Alanin und/oder L-alpha-Alaninamid.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STANFORD ROOK LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee